Abstract
Ripretinib is a multikinase inhibitor drug approved in 2020 by the FDA and in 2021 by EMA for use in the treatment of advanced gastrointestinal stroma......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
